



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Lei Cao
✉ BrawnyM80@163.com

†These authors have contributed equally to
this work

RECEIVED 13 November 2024
ACCEPTED 14 November 2024
PUBLISHED 26 November 2024

CITATION
Fu C, Du H, Wang Q, Zhu W, Bian G,
Zhong Z, Wang Y and Cao L (2024)
Corrigendum: Case report: A golden tail of
immunotherapy: significant tail effect in a
chemotherapy-resistant advanced pulmonary
sarcomatoid carcinoma patient treated by
Sintilimab combined with Anlotinib.
Front. Immunol. 15:1527232.
doi: 10.3389/fimmu.2024.1527232

COPYRIGHT
© 2024 Fu, Du, Wang, Zhu, Bian, Zhong, Wang
and Cao. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib

Chenghao Fu^{1,2†}, Haonan Du^{1†}, Qiang Wang^{3†}, Weiyu Zhu¹,
Guangli Bian⁴, Zhujuan Zhong⁵, Yuheng Wang² and Lei Cao^{6*}

¹Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China, ²Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China, ³Department of Thoracic Surgery, Taizhou Fourth People's Hospital, Taizhou, Jiangsu, China, ⁴Department of Radiology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China, ⁵Department of Pathology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China, ⁶Department of Oncology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu, China

KEYWORDS

tail effect, immunotherapy, cancer therapy, PSC, ICI, Sintilimab

A Corrigendum on

Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib

By Fu C, Du H, Wang Q, Zhu W, Bian G, Zhong Z, Wang Y and Cao L (2024). *Front. Immunol.* 15:1452195. doi: 10.3389/fimmu.2024.1452195

In the published article, there was an error in affiliations 4, 5, 6. Instead of “The First People’s Hospital of Suqian”, it should be “The Affiliated Suqian First People’s Hospital of Nanjing Medical University”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.